班_老虎社区_美港股上老虎 - 老虎社区

班

康方生物盘中涨超8% 康方生物依沃西与K药头对头研究获显著阳性结果

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":603969722180896,"tweetId":"603969722180896","gmtCreate":1788490584676,"gmtModify":1788491314353,"author":{"id":4113521397048440,"idStr":"4113521397048440","authorId":4113521397048440,"authorIdStr":"4113521397048440","name":"小朋戈","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p>班</p></body></html>","htmlText":"<html><head></head><body><p>班</p></body></html>","text":"班","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/603969722180896","repostId":2664383605,"repostType":2,"repost":{"id":"2664383605","kind":"news","pubTimestamp":1788487320,"share":"https://www.laohunote.com/m/news/2664383605?lang=zh_CN&edition=full","pubTime":"2026-09-04 10:02","market":"hk","language":"zh","title":"康方生物盘中涨超8% 康方生物依沃西与K药头对头研究获显著阳性结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383605","media":"新浪港股","summary":"9月4日，$康方生物$盘中涨超8%。9月3日，康方生物宣布，依沃西单抗头对头对比$K$药一线治疗PD-L1阳性晚期非小细胞肺癌的三期临床HARMONi-2达到OS关键次要终点，取得具有统计学显著性和临床获益的阳性结果。截至目前，依沃西已在多项头对头对比PD-1/L1疗法的全球Ⅲ期临床中，取得OS和PFS双阳性结果，未来有望凭借更优疗效撬动既有市场格局。","content":"<html><head></head><body><p style=\"text-align: left;\">9月4日，<a href=\"https://laohu8.com/S/09926\">康方生物</a>盘中涨超8%。截至发稿，股价上涨8.04%，现报98.1港元，成交额15亿港元。</p><p style=\"text-align: left;\">此外，诺诚健华升逾2%，和黄医药、四环医药、翰森制药升近2%。</p><p style=\"text-align: left;\">9月3日，康方生物宣布，依沃西单抗头对头对比<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>药一线治疗PD-L1阳性（TPS≥1%）晚期非小细胞肺癌（NSCLC）的三期临床HARMONi-2达到OS关键次要终点，取得具有统计学显著性和临床获益的阳性结果。截至目前，依沃西已在多项头对头对比PD-1/L1疗法的全球Ⅲ期临床中，取得OS和PFS双阳性结果，未来有望凭借更优疗效撬动既有市场格局。</p><p style=\"text-align: left;\">公开资料显示，帕博利珠单抗是开启肿瘤免疫治疗1.0时代最具代表性的药物，推动了肺癌治疗的重大进步，成为全球商业化最成功的创新药物之一。在帕博利珠单抗的基础上，依沃西进一步让患者实现显著获益，展现了依沃西作为下一代肿瘤免疫基石药物的突破性临床价值和巨大商业化价值潜力。</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/09e454814ff665aeb70cdb70bfdecf5e\" data-align=\"center\" tg-width=\"973\" tg-height=\"602\"/><span></span></p></body></html>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康方生物盘中涨超8% 康方生物依沃西与K药头对头研究获显著阳性结果</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康方生物盘中涨超8% 康方生物依沃西与K药头对头研究获显著阳性结果\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-04 10:02 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-04/doc-iniqrpqw4027860.shtml><strong>新浪港股</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9月4日，康方生物盘中涨超8%。截至发稿，股价上涨8.04%，现报98.1港元，成交额15亿港元。此外，诺诚健华升逾2%，和黄医药、四环医药、翰森制药升近2%。9月3日，康方生物宣布，依沃西单抗头对头对比K药一线治疗PD-L1阳性（TPS≥1%）晚期非小细胞肺癌（NSCLC）的三期临床HARMONi-2达到OS关键次要终点，取得具有统计学显著性和临床获益的阳性结果。截至目前，依沃西已在多项头对头...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-04/doc-iniqrpqw4027860.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","relate_stocks":{},"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-04/doc-iniqrpqw4027860.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2664383605","content_text":"9月4日，康方生物盘中涨超8%。截至发稿，股价上涨8.04%，现报98.1港元，成交额15亿港元。此外，诺诚健华升逾2%，和黄医药、四环医药、翰森制药升近2%。9月3日，康方生物宣布，依沃西单抗头对头对比K药一线治疗PD-L1阳性（TPS≥1%）晚期非小细胞肺癌（NSCLC）的三期临床HARMONi-2达到OS关键次要终点，取得具有统计学显著性和临床获益的阳性结果。截至目前，依沃西已在多项头对头对比PD-1/L1疗法的全球Ⅲ期临床中，取得OS和PFS双阳性结果，未来有望凭借更优疗效撬动既有市场格局。公开资料显示，帕博利珠单抗是开启肿瘤免疫治疗1.0时代最具代表性的药物，推动了肺癌治疗的重大进步，成为全球商业化最成功的创新药物之一。在帕博利珠单抗的基础上，依沃西进一步让患者实现显著获益，展现了依沃西作为下一代肿瘤免疫基石药物的突破性临床价值和巨大商业化价值潜力。","news_type":1,"symbols_score_info":{"09926":2.1,"KURE":0.6}},"isVote":1,"tweetType":1,"viewCount":0,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/603969722180896"}